KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Inventory (2016 - 2025)

Sarepta Therapeutics has reported Inventory over the past 10 years, most recently at $914.7 million for Q4 2025.

  • For Q4 2025, Inventory rose 21.97% year-over-year to $914.7 million; the TTM value through Dec 2025 reached $914.7 million, up 21.97%, while the annual FY2025 figure was $914.7 million, 21.97% up from the prior year.
  • Inventory for Q4 2025 was $914.7 million at Sarepta Therapeutics, down from $1.1 billion in the prior quarter.
  • Over five years, Inventory peaked at $1.1 billion in Q3 2025 and troughed at $186.2 million in Q4 2021.
  • A 5-year average of $445.8 million and a median of $278.6 million in 2021 define the central range for Inventory.
  • Biggest five-year swings in Inventory: dropped 23.32% in 2022 and later surged 152.04% in 2025.
  • Year by year, Inventory stood at $186.2 million in 2021, then increased by 9.54% to $204.0 million in 2022, then skyrocketed by 58.29% to $322.9 million in 2023, then soared by 132.29% to $750.0 million in 2024, then grew by 21.97% to $914.7 million in 2025.
  • Business Quant data shows Inventory for SRPT at $914.7 million in Q4 2025, $1.1 billion in Q3 2025, and $994.0 million in Q2 2025.